Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
Mots clés
Biomarkers
Metastatic cSCC
Molecular targeted therapies
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Colorectal carcinoma
Sonic Hedgehog
Cemiplimab
ADN tumoral circulant
Immunohistochemistry
BRAFV600-mutant melanoma
Prevention
Wnt
Gastric bypass
Metastatic
Advanced melanoma
Anti-CTLA-4
ALK
EGFR
Abscopal effect colorectal cancer intratumoral immunotherapy liver metastases radiofrequency
Allelic imbalance
Immunomodulation
Cutaneous squamous cell carcinoma
Safety
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Chemotherapy
Adverse events
Resistance
Androgen insensitivity
Non-small cell lung cancer
Dabrafenib
Follow-up
Bisphosphonates bone lesion case report histiocytosis Langerhans cell histiocytosis review
Systemic therapy
Adjuvant
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Anti-PD1 blockade
Colorectal cancer
Antineoplastic agents
Melanoma
Radiotherapy
Targeted therapy
BRAF V600-mutation
Anti-PD-1
Biomarkers Colonic neoplasms Machine learning Prognosis Tumour infiltrating lymphocytes
Osimertinib
Mesenchymal stromal cells
Cancer bronchique non à petites cellules
Beta-catenin
Body mass index
Invasive cutaneous squamous cell carcinoma
Colon cancer
Advanced
Surgical excision
BRAF V600E
Lung adenocarcinoma
AML
2-chlorodeoxyadenosine
Chemoresistance
Langerhans cell histiocytosis
Bariatric surgery
Trametinib
Children
Circulating cell-free DNA
Survival
Locally advanced
Adjuvant FOLFOX
Treatment
BRAF
Biliopancreatic diversion
AZD9291
Histiocytosis
Antibody-drug conjugate
Acute generalized exanthematous pustulosis
Prognostic
Immune checkpoint inhibitor
Plasma
Merkel cell carcinoma
Anti-Tumor pharmacology
Anti-PD-1 antibody
Adjuvant therapy
BRAFV600E
TNM classification
Staging
Prognosis
Abscopal effect
ACTH
Crizotinib
Abdominal pain
BRAFV600E mutation
Cancer
Nivolumab
Polyomavirus
Diagnosis
Immunotherapy
Assisted reproductive techniques
Biomarker
ALK rearrangement
Anti-PD1
Radiofrequency ablation
Circulating tumor DNA